Y-mAbs Therapeutics (NASDAQ:YMAB) stock peaked at $54.1 in late 2020, fueled by high hopes for its cancer treatment, Omburtamab. However, the FDA's 2020 Refusal to File and subsequent Complete ...
Last year, the FDA hit YMAB with a CRL for its neuroblastoma drug omburtamab. The company will need to do a new trial to get approval. Their restructuring will get them through mid-2024 with existing ...
NEW YORK, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback